Pharmaceutical Technology

FEBRUARY 9, 2023

Buntanetap tartrate is under clinical development by Annovis Bio and currently in Phase III for Parkinson’s Disease. According to GlobalData, Phase III drugs for Parkinson’s Disease have a 46% phase transition success rate (PTSR) indication benchmark for progressing into Filing rejected/Withdrawn.

Clinical Trials 100

Clinical Trials Clinical Trials Drugs Development 100

Pharmaceutical Technology

FEBRUARY 9, 2023

Buntanetap tartrate is under clinical development by Annovis Bio and currently in Phase III for Alzheimer’s Disease. According to GlobalData, Phase III drugs for Alzheimer’s Disease have a 9% phase transition success rate (PTSR) indication benchmark for progressing into Filing rejected/Withdrawn. Buy the report here.

Clinical Trials 100

Clinical Trials Clinical Trials Drugs Development 100

Pharmaceutical Technology

JUNE 6, 2023

According to Globaldata, it is involved in 1 clinical trial, which is ongoing. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). The drug candidate is administered by intravenous route.

RNA 100

RNA Protein Antibody Vaccination 100

Pharmaceutical Technology

MAY 31, 2023

ATRN-119 is under clinical development by Aprea Therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. The drug candidate is administered through oral route.

Production 100

Production Clinical Trials Clinical Trials Development 100

Pharmaceutical Technology

MARCH 2, 2023

Povetacicept is under clinical development by Alpine Immune Sciences and currently in Phase I for Systemic Lupus Erythematosus. According to GlobalData, Phase I drugs for Systemic Lupus Erythematosus have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. Buy the report here.

Protein 100

Protein Engineer Clinical Trials Clinical Trials 100

The Pharma Data

NOVEMBER 30, 2020

(Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today provided an update on its COVID-19 vaccine program. pivotal Phase 3 trial update. Novavax completed enrollment of 15,000 participants in a pivotal Phase 3 clinical trial being conducted in the U.K.

Clinical Development 52

Clinical Development Vaccination Vaccine Development 52

Drug Discovery World

JANUARY 15, 2024

Amgen and NVIDIA Amgen has announced plans to advance drug discovery using NVIDIA’s DGX SuperPOD-powered insights from human datasets. Chiesi and Oak Hill Bio Chiesi Group and Oak Hill Bio have entered a collaboration to develop OHB-607, a clinical-stage investigational drug candidate to treat complications of extremely premature birth.

Drugs 59

Drugs Licensing Licensing Protein 59

Pharmaceutical Technology

MAY 31, 2023

Sym-021 is under clinical development by Les Laboratoires Servier and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. It is developed based on sympress platform technology.

Generic Drugs 100

Generic Drugs Hormones Manufacturing Development 100

pharmaphorum

APRIL 28, 2022

OMass Therapeutics has raised an impressive $100 million in a Series B financing that is said to be the largest ever for a UK biotech focusing on small-molecule drug development. Robinson is OMass’ founder and scientific advisor.

Protein 104

Protein Drugs Development Clinical Trials 104

pharmaphorum

JANUARY 13, 2022

Sanofi has joined a growing list of drugmakers going after alpha-synuclein targeting drugs for Parkinson’s disease, licensing a bispecific antibody from South Korea’s ABL Bio in a deal that could be worth more than $1 billion. The post Sanofi places $75m bet with ABL on popular Parkinson’s drug target appeared first on.

Antibody 98

Antibody Drugs Protein Licensing 98

pharmaphorum

MAY 30, 2022

For decades, RAS has existed as an elusive therapeutic target, and drugging this high-value oncogene was deemed impossible. Despite this, the first-ever FDA-approved KRAS G12C inhibitor has demonstrated that RAS is in fact druggable and that drugging this protein unlocks a world of successful therapeutic interventions.

Development 52

Development Drugs FDA Approval Clinical Trials 52

Pharmaceutical Technology

JUNE 5, 2023

BI-765063 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Hypopharyngeal Cancer. According to GlobalData, Phase I drugs for Hypopharyngeal Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase I. Buy the report here.

Production 100

Production Manufacturing Drugs Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 24, 2023

ACE-1334 is under clinical development by Merck and currently in Phase I for Lung Disease. According to GlobalData, Phase I drugs for Lung Disease have a 92% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. It is developed based on protein engineering platform.

Production 100

Production Vaccination Vaccine Engineer 100

Pharmaceutical Technology

JUNE 10, 2023

RT-002 is under clinical development by Revance Therapeutics and currently in Phase II for Upper Limb Muscle Spasticity. According to GlobalData, Phase II drugs for Upper Limb Muscle Spasticity does not have sufficient historical data to build an indication benchmark PTSR for Phase II. Buy the report here.

Development 130

Development Drugs Clinical Trials Clinical Trials 130

Pharmaceutical Technology

JUNE 10, 2023

RT-002 is under clinical development by Revance Therapeutics and currently in Phase II for Upper Limb Muscle Spasticity. According to GlobalData, Phase II drugs for Upper Limb Muscle Spasticity does not have sufficient historical data to build an indication benchmark PTSR for Phase II. Buy the report here.

Development 130

Development Drugs Clinical Trials Clinical Trials 130

XTalks

JANUARY 23, 2024

Among these, rare pediatric diseases present unique challenges and opportunities for rare disease drug development. Pediatric growth hormone deficiency (PGHD) is one such condition, affecting a child’s growth and development.

Development 72

Development Hormones Drugs Trials 72

Roots Analysis

FEBRUARY 27, 2024

On November 1, 2019, Avacta Group and ADC Therapeutics have announced a collaboration agreement for the development of novel drug candidates. The firm also has the right to obtain exclusive licenses to the Affimer proteins for clinical development and commercialization.

Antibody 52

Antibody Licensing Licensing Contract Manufacturing 52

Pharmaceutical Technology

MARCH 1, 2023

Nedisertib is under clinical development by Merck and currently in Phase I for Neuroendocrine Tumors. According to GlobalData, Phase I drugs for Neuroendocrine Tumors have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. Buy the report here. It is a new chemical entity.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Pharmaceutical Technology

MARCH 1, 2023

Nedisertib is under clinical development by Merck and currently in Phase I for Head And Neck Cancer Squamous Cell Carcinoma. According to GlobalData, Phase I drugs for Head And Neck Cancer Squamous Cell Carcinoma have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Pharmaceutical Technology

FEBRUARY 26, 2023

CUE-102 is under clinical development by Cue Biopharma and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase I drugs for Metastatic Colorectal Cancer have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. Buy the report here.

Drugs 100

Drugs Clinical Trials Clinical Trials Development 100

Pharmaceutical Technology

FEBRUARY 26, 2023

CUE-102 is under clinical development by Cue Biopharma and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData, Phase I drugs for Gastroesophageal (GE) Junction Carcinomas have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II.

Drugs 100

Drugs Clinical Trials Clinical Trials Development 100

Pharmaceutical Technology

MARCH 23, 2023

Seagen specialises in developing antibody-drug conjugates (ADCs) which will complement Pfizer’s oncology portfolio. Seagen will maintain its operations in the Seattle area and will leverage Pfizer’s protein-engineering capabilities to develop next-generation biologics.

Licensing 147

Licensing Licensing Sales Trials 147

XTalks

APRIL 11, 2024

RELATED ON-DEMAND XTALKS WEBINAR: Leveraging Digital Biomarkers to Generate Real-World Physiological and Behavioral Data in CNS Clinical Studies Register for this free webinar to learn about an AI-based, multi-domain digital biomarker platform designed to provide objective, diverse and home-based patient data collection in CNS clinical trials.

Clinical Trials 110

Clinical Trials Clinical Trials Development Clinical Development 110

XTalks

OCTOBER 20, 2023

Clinical-stage genome editing company Intellia Therapeutics has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to start a pivotal phase III trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy.

In-Vivo 52

In-Vivo Gene Editing Trials Gene 52

The Pharma Data

JANUARY 31, 2021

The phase 1 clinical trial was a randomized, double-blind and placebo-controlled study in 150 adult and elderly participants. The phase 1 clinical trial was a randomized, double-blind and placebo-controlled study in 150 adult and elderly participants. . CHENGDU, China , Feb. S-Trimer is intended to be adjuvanted.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

The Pharma Data

JANUARY 3, 2021

Food and Drug Administration cleared Investigational New Drug Application. United Kingdom Medicines and Healthcare Products Regulatory Agency authorized Clinical Trial Application. About the INZ701-101 Phase 1/2 Clinical Trial of INZ-701 in Adults with ENPP1 Deficiency. BOSTON, Jan.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Containment 52

XTalks

JULY 17, 2023

In a significant development, Astellas Pharma announced that the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) had accepted their applications for Priority Review and Marketing Authorization respectively for zolbetuximab. In both trials, approximately 38 percent of the screened patients had CLDN18.2-positive

Clinical Trials 95

Clinical Trials Clinical Trials Trials Antibody 95

Drug Discovery World

JANUARY 19, 2023

A pilot Phase IIa clinical trial evaluating Abionyx Pharma’s CER-001 as a treatment for septic patients at high risk of developing acute kidney injury (AKI) has met its primary endpoint. Endothelial biomarkers demonstrated a significant protective effect of CER-001.

Drugs 52

Drugs Trials Clinical Trials Clinical Trials 52

The Pharma Data

DECEMBER 22, 2020

AVA6000 has been shown in animal models to significantly increase the amount of active drug in a tumour compared with the heart and should thereby improve tolerability and achieve better clinical outcomes for patients. Dosing of first patients will commence when we have responded to that feedback and received approval to proceed.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Development 52

The Pharma Data

JULY 22, 2021

(NYSE: PFE) today announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC® (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The companies will equally share worldwide development costs, commercialization expenses, and profits. Chief Executive Officer at Arvinas.

Protein 52

Protein Development HR Hormones 52

Pharmaceutical Technology

JULY 7, 2022

Often referred to as a type of gene-modified cell therapy, CAR-T cell therapies involve genetically modifying a patient’s own T cells to produce a protein that enables them to identify and kill cancer cells. Using a similar treatment to target solid tumours could be the industry’s next major milestone. Securing the supply chain.

Gene Therapy 245

Gene Therapy Gene Medicine Genetics 245

Camargo

JULY 27, 2021

When developing a clinical development program for these increasingly popular therapies, it is important that sponsors use modeling and pharmacokinetic (PK) analysis to evaluate parameters that can be measured while dosing with gene therapy drugs, to characterize exposure-response data and inform rational dosing.

Gene Therapy 238

Gene Therapy Gene Gene Editing Genetics 238

pharmaphorum

MARCH 10, 2021

With so many novel drug candidates for Alzheimer’s disease failing in clinical development, researchers in the US have started using artificial intelligence (AI) to screen already-approved therapies for activity against the neurodegenerative disorder. .

Clinical Trials 93

Clinical Trials Clinical Trials Trials FDA Approval 93

XTalks

MAY 9, 2024

XTALKS CLINICAL EDGE: Issue 2 — Genmab’s Interview Xtalks Clinical Edge is a magazine for clinical research professionals and all who want to be informed about the latest trends and happenings in clinical trials. The next generation of drug discovery and development is an exciting prospect.

Antibody 52

Antibody Clinical Trials Clinical Trials Medicine 52

The Pharma Data

DECEMBER 13, 2020

As part of the collaboration, Hummingbird will be leveraging Tempus’ AI-enabled platform and proprietary data, as well as joining its TIME Trial® Network, for rapid identification, site activation and efficient enrollment of cancer patients who have NRG1 fusions and meet eligibility criteria for HMBD-001 clinical trials.

Clinical Development 52

Clinical Development Medicine Development Antibody 52

The Pharma Data

JANUARY 13, 2021

(NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for HPN217 for the treatment of multiple myeloma. About the Phase 1/2 Trial for HPN217. NYSE: ABBV).

Drugs 52

Drugs Clinical Trials Clinical Trials Containment 52

pharmaphorum

MAY 13, 2021

The first patient was recruited in The Newcastle upon Tyne Hospitals NHS Foundation Trust, one of three UK sites for the clinical trial and part of 55 globally, across 15 countries. The trial is expected to enrol 99 ambulatory male patients, aged four to seven.

Gene Therapy 102

Gene Therapy Gene Trials Protein 102